Scancell updates protocol for UK trial in melanoma patients
15th Jun 2022 15:58
(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.
Read moreScancell opens recruitment for cancer therapy trial
11th Apr 2022 13:10
(Sharecast News) - Immunotherapy developer Scancell announced on Monday that its phase 1 and 2 clinical trial with 'Modi-1' is open for recruitment.
Read moreScancell treats first patient in melanoma tumour trial
19th Nov 2021 13:49
(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell announced on Friday that the enrolment and treatment of the first patient had taken place in its multicentre phase 2 clinical trial of its 'SCIB1' tumour treatment at the Churchill Hospital in Oxford.
Read moreScancell gets MHRA approval for Modi-1 clinical trial
26th Aug 2021 12:38
(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that the UK Medicines and Healthcare products Regulatory Authority (MHRA) has approved the clinical trial application to initiate the first-in-human phase 1 and 2 clinical study of 'Modi-1'.
Read moreScancell chooses needle-free tech for Covid vaccine candidates
17th Aug 2021 15:32
(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell has selected the PharmaJet needle-free injection system to administer its two SARS-CoV-2 vaccine candidates for Covid-19, 'SCOV1' and 'SCOV2', in its 'COVIDITY' phase 1 clinical trial, it announced on Tuesday.
Read moreScancell makes progress with 'Covidity' trial plans
22nd Jun 2021 15:21
(Sharecast News) - Immunotherapy developer Scancell updated the market on 'Covidity' clinical trial plans, and the publication of preclinical data on two vaccine candidates from the research programme.
Read moreScancell ends clinical development partnership with Cancer Research UK
3rd Feb 2021 14:53
(Sharecast News) - Novel immunotherapy developer Scancell updated the market on its SCIB2 clinical development partnership with Cancer Research UK on Wednesday, reporting that due to the impact of the Covid-19 pandemic and Cancer Research UK's re-evaluation of its collaboration model, the parties had agreed to end their clinical development partnership.
Read moreScancell selects Covid-19 vaccine candidate for development and trials
18th Dec 2020 10:17
(Sharecast News) - Immunotherapy developer Scancell has selected its Covid-19 vaccine candidate 'SN14' for further development and clinical trials, it announced on Friday.
Read moreScancell reaches Covid-19 collaboration agreement with Cobra Biologics
2nd Oct 2020 09:18
(Sharecast News) - Immunotherapies developer Scancell Holdings has entered into a collaboration agreement with Cobra Biologics to manufacture the firm's Covid-19 vaccine.
Read moreScancell upbeat on publication of AvidiMab research
12th Jun 2020 12:59
(Sharecast News) - Cancer immunotherapy developer Scancell Holdings noted the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR) on Friday, titled 'Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement'.
Read moreDirector dealings: Scancell director lowers stake
28th Apr 2020 16:40
(Sharecast News) - Scancell revealed on Tuesday that non-executive director Martin Diggle had sold 1.5m ordinary shares in the AIM-listed biotechnology firm.
Read moreScancell's 'SCIB1' clears latest regulatory hurdle in US
3rd Feb 2020 14:20
(Sharecast News) - Cancer immunotherapy developer Scancell announced on Monday that its investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for 'SCIB1' has been approved.
Read moreScancell inks AvidiMab agreement with Chinese biotech company
16th Dec 2019 13:30
(Sharecast News) - Scancell Holdings on Monday signed a collaboration and non-exclusive research agreement with an unnamed Chinese biotechnology firm.
Read moreScancell signs collaboration agreement with antibody technology company
4th Sep 2019 08:58
(Sharecast News) - Cancer treatment developer Scancell has inked its first collaboration agreement with a "leading" antibody technology company for its new platform technology, AvidiMab.
Read moreScancell losses deepen as it presses on with development
20th Aug 2019 10:59
(Sharecast News) - Novel immunotherapies developer Scancell Holdings reported a deeper operating loss in its final results on Tuesday, to £6.73m compared to £4.91m in the 2018 financial year.
Read more